News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,021 Results
Type
Article (13817)
Company Profile (101)
Press Release (252103)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88067)
Career Advice (465)
Deals (15345)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6299)
Job Trends (6203)
News (150257)
Policy (14045)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23238)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (643)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (22)
Cell therapy (89)
Cervical cancer (4)
Clinical research (30944)
Collaboration (352)
Compensation (155)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (127)
Cystic fibrosis (37)
Data (663)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1324)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32215)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37590)
Executive appointments (400)
FDA (6735)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (19)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5880)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (162)
MASH (33)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9675)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1586)
Non-profit (595)
Northern California (729)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (53)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (29)
Peanut (10)
People (28982)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8054)
Phase II (13092)
Phase III (11747)
Pipeline (465)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2637)
Recruiting (17)
Regulatory (10139)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (746)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (31)
The Weekly (30)
United States (7424)
Vaccines (156)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (55)
Last 7 days (265)
Last 30 days (900)
Last 365 days (11751)
2025 (3878)
2024 (12502)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20150)
Australia (2616)
California (1777)
Canada (929)
China (247)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39516)
Florida (338)
Georgia (39)
Idaho (9)
Illinois (201)
India (16)
Indiana (136)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (263)
Massachusetts (1530)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (782)
New Mexico (7)
New York (531)
North Carolina (402)
North Dakota (2)
Northern California (729)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (458)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (746)
Tennessee (34)
Texas (236)
Utah (34)
Virginia (77)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,021 Results for "recce pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
April 23, 2025
·
5 min read
Press Releases
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
·
3 min read
Press Releases
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
November 27, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
April 11, 2025
·
8 min read
Press Releases
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
February 19, 2025
·
5 min read
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
January 23, 2025
·
5 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.
June 20, 2024
·
3 min read
Drug Development
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Recce Pharmaceuticals Ltd today announced it received Human Research Ethics Committee (HREC) approval to commence a Phase II trial assessing its lead candidate, RECCE® 327 (R327), as a topical, broad-spectrum gel for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
June 25, 2024
·
4 min read
1 of 26,603
Next
